Highlights PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Delayed Australian S.E. Other stock markets 10:16:39 2024-04-29 pm EDT			5-day change	1st Jan Change
0.094 ^AUD	+2.17%		0.00%	-14.55%

Apr. 22	Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	MT
Apr. 22	PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	Apr. 22	MT
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	Apr. 21	MT
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	Apr. 10	MT
Rights Issue: 1 new share @ 0.08 AUD for 4 existing shares	Mar. 17	FA
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	Feb. 16	MT
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	Jan. 01	MT
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	Nov. 13	CI
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	23-08-09	MT
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	23-08-01	MT
Us Fda Clears PYC Therapeutics Limited to Commence the First Ever Human Trial in Retinitis Pigmentosa Type 11	23-03-05	CI
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
PYC Therapeutics Files IND Application with US FDA for Retinitis Pigmentosa Medication	23-02-02	MT
PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration	23-02-01	CI
PYC Therapeutics Raises Stake in Vision Pharma to 95.2%	22-11-28	MT
PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials	22-11-06	CI
PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline	22-09-26	CI
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Highlights

Filters